Company Overview of University of California-San Francisco
University of California-San Francisco is an education institution offering programs such as biological, biomedical, pharmaceutical, nursing, social and behavioral sciences, dentistry, medicine, and nursing and pharmacy. The schools of the university include Continuing Medical Education, School of Dentistry, School of Medicine, School of Nursing, and School of Pharmacy. University of California- San Francisco was established in 1897 and is based in San Francisco, California. The university has endowment assets worth $873 million.
San Francisco, CA 94143
Founded in 2007
Key Executives for University of California-San Francisco
Professor of Tumor Biology and Cancer Research
Executive Director of News
Executive Director of Global Health Sciences
Compensation as of Fiscal Year 2014.
University of California-San Francisco Key Developments
University of California, San Francisco and the Centre for Drug Research and Development Signs Drug Development Agreement Collaboration to Take New Medications from Laboratory to Commercial Development Stage
Oct 16 14
University of California, San Francisco and The Centre for Drug Research and Development (CDRD), announced a collaborative affiliation to identify potential medications and develop them to the stage where they are commercially attractive to private sector partners. The agreement is designed to address a challenging problem in drug development: the so-called 'Valley of Death' between the discovery of a potential therapy and the point where it is of commercial interest to pharmaceutical or biotech companies or private sector investors. During this phase, the financial burden of continued research without return can often mean that a promising medication is never developed further. The collaboration is the first in the United States for CDRD, which has similar agreements with institutions around the world, including Oxford University and the Universities of Tokyo, and Sydney. A scientific team from CDRD will visit UCSF in November in order to explore specific collaborative opportunities with UCSF researchers. Researchers interested in meeting with CDRD to discuss possible collaborations are encouraged to contact Kaley Wilson, PhD, associate director of partnerships.
UC San Francisco Appoints Jennifer R. Grandis as Associate Vice Chancellor of Clinical and Translational Research to Begin in January 2015
Oct 7 14
Jennifer R. Grandis, MD, has been appointed as UC San Francisco's Associate Vice Chancellor of Clinical and Translational Research (AVC-CTR) on Oct. 6, 2014. She will begin her new post in January 2015 while also holding a faculty appointment as professor of Otolaryngology-Head and Neck Surgery. Jennifer will lead, manage and shape the strategic direction for broad elements of clinical and translational research enterprise including the Clinical & Translational Institute (CTSI). In addition, her responsibilities include serving as a liaison to national committees in the field and overseeing all aspects of clinical trials infrastructure and processes. Jennifer will be collaborating with multiple entities and other leaders on campus, including but not limited to, the Medical Center, the entire EVCP organization, the four Schools and Graduate Division, and key ORUs and centers on campus. Grandis will take over for Deborah Grady, MD, who served as the interim director of Clinical and Translational Science Institute (CTSI). Additionally, Grandis is Health Sciences Assistant Vice Chancellor for Research Program Integration.
UCSF Presents at 13th Annual BIO Investor Forum, Oct-07-2014 09:00 AM
Sep 12 14
UCSF Presents at 13th Annual BIO Investor Forum, Oct-07-2014 09:00 AM. Venue: The Palace Hotel, San Francisco, CA 94105, United States. Speakers: Celgene—Kristen Hege, MD, San Francisco Site Head, VP Translational Development, Hematology & Oncology; Assistant Professor.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|